EZH2 PROTACs outperform catalytic inhibitors in prostate cancer by targeting a methylation-independent function of PRC2
EZH2 PROTACs 通过靶向 PRC2 的甲基化非依赖性功能,在治疗前列腺癌方面优于催化抑制剂。
期刊:Oncogene
影响因子:6.9
doi:10.1038/s41388-025-03662-z.
Wanqing Xie,Qi Chu,Lourdes Brea,Guihua Zeng,Yuan Wang,Xiaodong Lu,Mohan Zheng,Corinne R Ley,Zhiquan Lei,Hongshun Shi,Joshua L Zhu,Lihu Gong,M Cynthia Martin,Xianglin Shi,Galina Gritsina,Arabela A Grigorescu,Hana Chandonnet,Xin Liu,Jonathan C Zhao,Gary E Schiltz,Jindan Yu